Employers’ benefit coverage decisions and the impact those decisions have on the market for rare disease / orphan drugs are a growing concern for biopharma companies
Independence Blue Cross (Independence) recently announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023
The leading specialty pharmacies were busy signing limited distribution drug agreements at the end of 2022. Here’s a round-up of the activities
Nobelpharma America Selects AllianceRx Walgreens and Total Care Rx to Distribute Hyftor
PANTHERx Rare announced that it has been selected by Aadi Bioscience (Aadi) as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound)
Investment positions Orsini Specialty Pharmacy for continued expansion of patient access and support services across therapies for highly complex and rare diseases
PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).
The Vistria Group, LP (Vistria) recently announced the acquisition of BioCare, Inc. (BioCare), a leading specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services